EyePoint, Inc. EYPT 深 沪
等待开盘 06-25 09:30:00 美东时间
14.40
+0.020
+0.14%
华盛通- 最 高14.85
- 今 开14.38
- 成交量 89.51万股
- 最 低 14.29
- 昨 收 14.38
- 总市值 12.07亿
- 52周最高 19.11
- 市盈率 静 --
- 换手率 1.07%
- 52周最低 9.40
- 委 比 93.17%
- 总股本 8384.13万
- 历史最高 39.40
- 量 比 0.71
- 振 幅 3.89%
- 历史最低 2.19
- 每 手 1
- 风险率 2.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞银上调超微公司目标价从455美元升至670美元，上调ARM目标价从260美元升至470美元；美银证券上调台积电目标价从490美元升至590美元
今日重点评级关注：Jones Trading：维持Definium Therapeutics"买入"评级，目标价从61美元升至74美元；韦德布什：维持Cerebras Systems"跑赢大市"评级，目标价从270美元升至280美元
今天 11:32
Guggenheim Reiterates Buy on EyePoint, Maintains $68 Price Target
Guggenheim analyst Yatin Suneja reiterates EyePoint (NASDAQ:EYPT) with a Buy and maintains $68 price target.
06-24 21:55
EyePoint Stockholders Approve Incentive Plan and Board Slate
The latest update is out from EyePoint Pharmaceuticals ( ($EYPT) ). EyePoint, I...
06-22 19:38
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. granted stock options to purchase up to 39,700 shares of its common stock to three new employees outside its 2023 Long-Term Incentive Plan, in accordance with NASDAQ Listing Rule 5635(c)(4). The options, with an exercise price of $12.08 per share, vest over four years and have a ten-year term. The Company is focused on developing therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU™, in Phase 3 trials...
06-16 11:00
EyePoint Pharma Bets Big on DURAVYU Pivotal Data
Eyepoint Pharma (($EYPT)) has held its Q1 earnings call. Read on for the main h...
05-20 11:18
EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint, Inc. announced its participation in three upcoming conferences: the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026; the Jefferies Global Healthcare Conference on June 3, 2026; and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Each fireside chat will be available via webcast and archived replay on the Company's website. EyePoint is focused on developing innovative therapeutics for retinal diseases, ...
05-19 11:00
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. granted stock options to eight new employees outside its 2023 Long-Term Incentive Plan, in accordance with NASDAQ Listing Rule 5635(c)(4). The options, totaling 158,100 shares, were granted on May 15, 2026, with an exercise price of $12.35 per share. The options vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly over the next three years, contingent on continued employment. The company...
05-18 11:00
EyePoint's late-stage eye drug trials to continue after safety panel review
EyePoint's late-stage eye drug trials to continue after safety panel review May 14 (Reuters) - EyePoint EYPT.O said on Thursday an independent safety committee found no new concerns in two late-stage trials of its experimental eye disease drug Duravyu and recommended the studies continue unchanged.
05-14 20:35
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
Eyepoint Pharma (($EYPT)) has held its Q1 earnings call. Read on for the main h...
05-08 10:20
